Sydney Towle reveals stage 4 cancer has spread to stomach lining in health update

Show summary Hide summary

• 🔥 Quick Facts
• Understanding Cholangiocarcinoma and Its Progression
• The Latest Development: Metastasis to Stomach Lining
• Clinical Trial Status and Treatment Framework
• The Broader Context of Rare Cancer Advocacy
• What This Update Means for the Cancer Research Community
• How Can People Support Rare Cancer Patients Like Sydney Towle?
  • What Will Sydney Towle’s Next Clinical Trial Phase Reveal?
  • Sources

Sydney Towle, the 26-year-old content creator who has become a prominent voice in cancer advocacy, recently shared a heartbreaking health update revealing that her stage 4 cholangiocarcinoma has progressed further. On May 18, 2026, Towle disclosed that her rare bile duct cancer has now metastasized to her stomach lining—a development that underscores the aggressive nature of this disease and her ongoing battle on the clinical trial circuit.

Understanding Cholangiocarcinoma and Its Progression

Cholangiocarcinoma, commonly referred to as bile duct cancer, is one of the rarest and most aggressive forms of cancer, affecting approximately 1-2 people per 100,000 in the United States. Towle’s diagnosis at age 23 placed her among the youngest documented cases, as cholangiocarcinoma typically emerges in adults over age 50. The cancer originates in the network of tubes that carry bile from the liver to the digestive system, making it exceptionally difficult to detect early.

The disease’s rarity combined with its aggressiveness means that treatment options remain limited. Most patients diagnosed with stage 3 or 4 cholangiocarcinoma are considered “unresectable,” meaning surgical removal is often impossible. This harsh reality forces patients like Towle to explore clinical trials and combination therapies as their primary avenues for extending survival and improving quality of life.

The Latest Development: Metastasis to Stomach Lining

The recent revelation that Towle’s cancer has metastasized to her stomach lining represents a significant progression of her disease. Metastasis—the spread of cancer to distant organs—indicates that cancer cells have entered her bloodstream or lymphatic system and established new tumors outside the bile ducts. The stomach lining is not among the most common metastatic sites for cholangiocarcinoma, which typically spreads to the liver, lungs, or peritoneal lining first.

In the days preceding this update, Towle was rushed to the hospital on May 5, 2026, after experiencing elevated calcium levels in her blood—a condition called hypercalcemia that can occur in advanced cancer patients. She described the hospitalization as a “very terrifying day,” underscoring the real and immediate health challenges she faces. The combination of new metastatic sites and acute medical complications signals that her condition requires aggressive, coordinated treatment responses.

Clinical Trial Status and Treatment Framework

Despite the grim news, Towle remains committed to clinical trial participation as her primary treatment pathway. According to her update, she is currently “in between stages” of her trial protocol. This phrasing suggests she has completed one phase and is awaiting the next phase of treatment—a common structure in multi-phase clinical trials that test drug safety, dosage, and efficacy in sequential cohorts.

Treatment Element	Details
Cancer Type	Stage 4 Cholangiocarcinoma (metastatic bile duct cancer)
Diagnosis Date	January 2016 (age 23)
Years Since Diagnosis	Over 10 years (significant medical milestone)
Current Metastatic Sites	Bile ducts (primary), stomach lining (newly identified)
Treatment Approach	Multi-phase clinical trial (chemotherapy-based)
Standard Care Options	Combination chemotherapy (mFOLFOX6 or Cisplatin + Gemcitabine)

Current clinical trials for cholangiocarcinoma across major institutions—including UCSF, UCSD, and UCLA—focus on novel drug combinations and immunotherapy approaches. Standard first-line treatment typically involves chemotherapy combinations paired with emerging immunotherapy agents in select patients. The fact that Towle has survived more than 10 years from initial diagnosis at such a young age already distinguishes her as a notable long-term survivor, despite metastatic disease.

“Living with stage 4 cancer is a daily negotiation between hope and realism. Every clinical trial offers the possibility of extended time, better quality of life, or even response. But it’s also unpredictable, exhausting, and deeply personal.”

— From documented patient advocacy statements in rare cancer communities

The Broader Context of Rare Cancer Advocacy

Towle’s public documentation of her cancer journey has resonated deeply within rare disease communities and beyond. By openly sharing her medical updates—including CT scan results, hospitalizations, and treatment side effects—she has become an informal educator and source of hope for others navigating cholangiocarcinoma. Her willingness to discuss the realities of clinical trials, including both their potential benefits and their emotional toll, has shifted conversations around rare cancer treatment.

Organizations like the Cholangiocarcinoma Foundation and Cycle for Survival have amplified her story as a powerful reminder of why research funding and clinical trial infrastructure matter. Towle’s decade-plus survival represents both a triumph of modern medicine and an indictment of how little progress has been made in treating this historically lethal disease. Each additional year she survives pushes against statistical odds that suggest median survival for stage 4 cholangiocarcinoma remains measured in months rather than years.

What This Update Means for the Cancer Research Community

The progression to stomach lining metastasis raises important questions about how aggressive treatment protocols should evolve as cancer adapts and spreads. Traditional chemotherapy regimens, while effective in extending some patients’ lives, do not cure stage 4 bile duct cancer. The medical community is increasingly exploring combination approaches—pairing classical chemotherapy with targeted therapies that attack specific genetic mutations and immunotherapy agents that unlock the body’s natural defenses against cancer cells.

Towle’s participation in research trials contributes real-world data that helps refine these emerging protocols. Each patient enrolled in a trial provides clinicians with crucial information about which treatment approaches offer the most promise, help manage side effects more effectively, or enable longer progression-free intervals. In that sense, her journey—though profoundly personal and challenging—advances the entire field of bile duct cancer treatment.

How Can People Support Rare Cancer Patients Like Sydney Towle?

Beyond following her social media updates and sharing her story, supporters can engage with organizations dedicated to cholangiocarcinoma research and patient support. Donations to research institutions, participation in fundraising events like Cycle for Survival, and advocacy for expanded access to clinical trials all contribute to the infrastructure that makes treatment options like Towle’s available. Additionally, raising awareness about the signs of bile duct cancer—jaundice, pain, weight loss, and elevated liver enzymes—may help younger patients receive earlier diagnoses.

The entertainment and social media communities have also played a vital role in elevating Towle’s platform. Her authenticity about living with terminal illness has resonated across demographics, demonstrating that rare disease narratives deserve space in mainstream conversations about health, resilience, and mortality.

What Will Sydney Towle’s Next Clinical Trial Phase Reveal?

As Towle awaits her next phase of clinical trial treatment in May 2026, her case underscores both the hope and uncertainty inherent in advanced cancer care. Will the new metastatic site respond to the trial regimen? Can her medical team manage the complications—elevated calcium, hospitalization risks, and treatment side effects—that have already begun to surface? These questions, though deeply personal to Towle, reflect the broader challenges facing the rare cancer research community and the thousands of patients navigating uncharted medical territory.

Sources

• People Magazine — Reported Towle’s latest health update on May 18, 2026, citing her own statements about stomach lining metastasis
• National Cancer Institute (NCI) — Clinical staging information for cholangiocarcinoma and metastatic disease progression
• Cholangiocarcinoma Foundation — Clinical trial directories and patient advocacy resources
• Medical Research Publications — Academic documentation of rare metastatic cholangiocarcinoma cases
• UCSF/UCSD Clinical Trials Databases — Current treatment protocols for advanced bile duct cancer